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FETAL RESEARCH
THE IMPACT ON FETAL RESEARCH OF THE REPORT OF
THE NATIONAL COMMISSION FOR THE PROTEC-
TION OF HUMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH.
ROBERT J. LEVINE, M.D.t
An assessment of the impact upon fetal research of the Report
and Recommendations (Report) of the National Commission for the
Protection of Human Subjects of Biomedical and Behavioral Re-
search1 depends, to some extent, upon one's perspective. This article
will focus upon the impact of the Commission's Report as perceived by
a physician-investigator.
In the past three years there has been a substantial decrease in the
amount of fetal research performed in the United States. This de-
crease reflects the effects of multiple social and political forces that
were operative before the Commission was convened and which con-
tinued during its deliberations and after its report was issued. A point
by point comparison of the Commission's Report with previous ex-
pressions of national public policy indicates that the Report's overall
impact should be to encourage the conduct of high quality fetal re-
search. However, due to the aforementioned social and political factors,
it is not yet clear whether the Report will have this effect. This article
will examine these developments in detail.
Another area of difficulty involves the conceptual and semantic
problems that undermine most efforts to discuss the law as it relates
to research. This article will identify some of the semantic problems
perpetuated by the Report and suggest an approach to the resolution
of one - the spurious distinction between therapeutic and nonthera-
peutic research.
I. THE DECREASE IN FETAL RESEARCH -
IMPACT OF THE COMMISSION'S REPORT
A. Decreased Research on and Involving the Fetus
During the past three years there has been a substantial decrease
in the amount of research done on the fetus. This is illustrated by re-
t Professor of Medicine and Lecturer in Pharmacology, Yale University School
of Medicine. Consultant, National Commission for the Protection of Human Subjects
of Biomedical and Behavioral Research. M.D., George Washington University Medical
School, 1958.
1. NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF Bio-
MEDICAL AND BEHAVIORAL RESEARCH, REPORT AND RECOMMENDATIONS: RESEARCH ON
THE FETUS, (DHEW Pub. No. (OS) 76-127, 1975), also printed in 40 Fed. Reg.
33,530 (1975) (partially codified in 45 C.F.R. §§ 46.101-.301 (1976)) [hereinafter cited
as COMMISSION'S REPORT]. For the reader's convenience, chapters VIII and IX are
reprinted herein at 300-24, and unless otherwise indicated, all citations to the
Commission's Report refer to these pages.
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viewing the experience of the National Institutes of Health (NIH).2 In
March, 1976, the Office for Protection from Research Risks (OPRR)
at NIH reviewed all proposals to do fetal research received by NIH
since July, 1974 - the date the National Research Act placed a mora-
torium on some sorts of fetal research.3 In twenty-one months, NIH
had received only three proposals to do research on the fetus, each of
which was for either renewal or continuation of ongoing research
programs.' All three would have been classified as therapeutic research
as defined in the Commission's Report. 5 In two of the proposals, the
research maneuver was the use of ultrasound as an aid to determining
fetal size. The third involved administration of blood transfusions to
the fetus in utero. In the latter proposal, blood was to be administered
only to fetuses who required it due to severe congenital anemia.
Performance of this maneuver presented a risk of premature induction
of labor, and if labor is induced before the fetus becomes viable a non-
viable fetus is delivered which will certainly die.' Thus, a risk of
2. Conversation with Dr. Donald T. Chalkley, Director of the Office for Pro-
tection from Research Risks (OPRR), National Institutes of Health (NIH)
(December 13, 1976). During the course of this conversation, the author's impres-
sions of the effects of various events on the quantity and quality of fetal research
were supported.
3. Pub. L. No. 93-348, Title II, § 213, 88 Stat. 353 (1974). It should be noted
that NIH distinguishes between research on the fetus and research involving the fetus.
In the former category, a maneuver performed for research purposes actually touches
the fetus. This touching might be through an instrument, administration of a drug,
or the use of X-rays or ultrasound. Research involving the fetus is, in general, research
in which the subjects are pregnant women and there is some cause to suspect that there
might be some influence on the fetus. However, there is no direct touching of the
fetus. For example, anything that alters the physiologic state of the mother might be
viewed as having a potential effect on the fetus. Some types of research maneuvers
which are classified as involving the fetus - e.g., amniocentesis performed for research
purposes - are substantially more likely to have an adverse effect on the fetus than
are some classified as research on the fetus - e.g., ultrasound done for purposes of
determining fetal size (which presents no known risk either to the fetus or the mother)
4. NIH grants and contracts are ordinarily funded for one year terms. At the
time an award is made there is also a statement of a period (usually three to five
years) during which financial support - usually at approximately the same level -
may be expected to continue. A continuation application is a request by an investigator
to continue funding of a project for another year within the initially stated period
of support. A renewal application is a request for a new period of support (usually
three to five years) of an on-going project at the time the initial period is ending.
A new application is a request to initiate a new project.
5. "Therapeutic research" is defined in the Report as "research designed to im-
prove the health condition of the research subject by prophylactic, diagnostic or treat-
ment methods that depart from standard medical practice but hold out a reasonable
expectation of success." COMMISSION'S REPORT, supra note 1, at 40 Fed. Reg.
33,532 (1975).
6. The terms viable, nonviable, previable and death have carefully defined tech-
nical meanings. For a full elaboration of these and other terms useful in discussing
the fetus at various stages of its development see Levine, Viability and Death of the
Human Fetus: Biologic Definitions, 23 CLINICAL RESEARCH 211-16 (1975). Viability
is a term applied to a fetus which, taking into account its present circumstances, is
[VOL. 22 : p. 297
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this maneuver is the induction of an abortion. However, it was con-
fidently estimated that the risks to the fetus of transfusion would be
much smaller than the risks of not transfusing.
As of December 13, 1976, no new research grant or contract
applications to do research on the fetus had been funded by NIH
since the moratorium. There is no data as to how many proposals
there were between March and December, 1976, but it has been esti-
mated that the number is extremely low.7 In summary, since July,
1974, NIH has funded very little research on the fetus and has re-
ceived very few proposals to do such research. Currently funded
projects present either no known risk or, in one case, risks that are
clearly outweighed by anticipated direct benefits to the fetus.
B. Factors Contributing to the Decline in Fetal Research
Many persons assume that the decline in the amount of fetal
research is in some way connected with the activities of the Commis-
sion. Yet there have been so many events during the past four years
that have influenced the climate in which research is done and the
motivations of those who do the research that it is quite impossible
to assess the impact of the Commission.8
Early in 1973, the United States Supreme Court in Roe v. Wade'
and Doe v. Bolton'° established the right of a pregnant woman to have
predictive of the likelihood that it will become an infant capable of maintaining life
independently of the mother. Nonviability is a status which may exist in utero or
ex utero. The diagnosis of nonviability is absolutely predictive of death. Previability
describes the status of a presumed viable fetus in utero prior to the twentieth week
of gestation. Spontaneous or induced delivery of a previable fetus will result in a
fetus that will be classified as nonviable ex utero. Death is the total and permanent
cessation of those biologic functions that, taken together, provide grounds for classify-
ing a fetus (as a total integrated organism) alive. It is possible, indeed usual, for
some organs, tissues, and cells to remain alive for varying periods of time after the
total organism is dead.
Unfortunately, the definitions developed by the Commission provide no lan-
guage which one might use to discuss the probability of a fetus' survival after spon-
taneous or induced delivery. See COMMISSION'S REPORT, supra note 1, at 40 Fed.
Reg. 33,531-32 (1975).
7. Conversation with Dr. Donald T. Chalkley, supra note 2.
8. A chronology of some of the more important events that have recently in-
fluenced fetal research:
January 1973 Supreme Court: Roe and Doe decisions on abortion.
November 1973 DHEW proposed regulations on protection of subjects with
"limited capacities to consent."
April 1974 Indictment of Dr. Sabath et al for "grave-robbing."
1974-1975 Development of state laws proscribing various categories of fetal
research.
July 1974 National Research Act establishes Commission, moratorium on
fetal research.
February 1975 Conviction of Dr. Edelin for manslaughter.
May 1975 Commission Report: Research on the Fetus.
9. 410 U.S. 113 (1973).
10. 410 U.S. 179 (1973).
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an abortion during the first two trimesters of pregnancy for whatever
reasons she and her doctor consider appropriate. It is generally as-
sumed that these decisions greatly encourage fetal research because
they increased the availability of fetuses upon which to do research.
However, this is not the case. Even before 1973 there were many
more fetuses available than researchers had the capacity to study.
These fetuses became available through therapeutic abortions and
spontaneous miscarriages. The effect of the Roe and Doe decisions was
merely to increase an already excessive supply. This does not mean
that there was a large amount of fetal research; rather, there were
relatively few people having the appropriate training, interests, and
expensive equipment necessary to do good fetal research." However,
the Roe and Doe decisions did have two effects: one which might
eventually inhibit one type of fetal research, and the other which tends
to facilitate one particularly important category of fetal research.
For some types of research on the fetus, e.g., research done to
determine the feasibility of transplanting fetal organs, it is essential to
have relatively large, intact, living but nonviable fetuses as subjects.
Because of the Roe and Doe decisions there has been a tendency to
perform abortions much earlier in pregnancy, since the delays asso-
ciated with certifying an abortion as "therapeutic" no longer exist.
The trend toward a diminished availability of such fetuses began with
the Roe and Doe decisions and was accelerated following the Edelin
decision. 12 In 1976, fetal availability was approximately twenty-five
percent of what it was prior to 1973.' Some investigators have
complained that the progress of their research which is dependent upon
the availability of this type of fetus has, in fact, been delayed.
On the other hand, the Roe and Doe decisions facilitated the con-
duct of some very important fetal research of the sort that is or
should be initiated shortly before an abortion procedure. 14  Now
11. As a corollary, it is often stated that one reason to restrict or prohibit fetal
research is that it would remove the motivations of researchers to encourage abortions
so as to make more fetuses available for their research. This is clearly incorrect; there
is no numerical deficiency that any researcher might wish to supply.
12. See notes 27-29 and accompanying text infra.
13. Conversation with Dr. Donald T. Chalkley, supra note 2.
14. There are two types of research, which if they are to be done at all, are most
appropriately initiated shortly before an abortion procedure. The first is research in
which the proposed objective cannot be achieved unless the fetus can be examined
shortly after it is aborted. This most commonly entails administration of a drug to
the mother before the abortion is begun and the examination, shortly after the abor-
tion, of the tissues of the fetus to determine: 1) whether the drug has gotten into the
tissues and 2) if so, what effects (either good or bad) it might have had. Development
of rational drug therapy for the pregnant woman and for the fetus is dependent upon
[VOL. 22 : p. 297
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healthy women can have abortions performed in clinics or hospitals
according to a schedule around which the research can be planned
rather than having illegal abortions of which investigators may not
even be aware.
In 1973 and 1974, the Department of Health, Education and Wel-
fare (HEW) proposed regulations to safeguard the rights and welfare
of research subjects having "limited capacity to consent"; such per-
sons - in the view of HEW - include the fetus, children, prisoners
and the institutionalized mentally infirm.15 These proposals produced
considerable concern and anxiety in the biomedical research com-
munity.' In general there were several kinds of problems that were
presented by the proposed regulations."7 First, they would have created
the performance of such research. For example, it would be absurd to attempt to
treat an infection in the fetus with a drug that did not even penetrate the fetal tissue.
It is highly uncommon for drugs to produce any harm to the fetus that could not be
anticipated from the results of research done before such research on the fetus is
performed. See Levine, Appropriate Guidelines for the Selection of Human Subjects
for Participation in Biomedical and Behavioral Research 64-69 (February 2, 1976)
(paper presented to the National Commission for the Protection of Human Subjects
of Biomedical and Behavioral Research, Feb. 2, 1976) (on file at the offices of the
National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research, Westwood Building, Room 125, 5333 Westbard Avenue, Bethesda,
Maryland 20016). For an elaboration of the consequences of not proceeding with
this sort of research, see Mirkin, Impact of Public Policy on the Development of
Drugs for Pregnant Women and Children, 23 CLINICAL RESEARCH 233-37 (1975);
Shirkey, Therapeutic Orphans, 72 J. PEDIATRICS 119 (1968).
The second type of research that it seems most appropriate to do in antici-
pation of abortion is that in which there is cause to suspect that some harm might
befall the fetus as a consequence of the research. The sort of harm with which one is
most commonly concerned is that a maneuver might induce premature labor. If this
is done at a time when the fetus is previable, the delivered fetus will be nonviable
and will die. Usually in the early stages of such research it is not known whether
premature labor will be induced. However, during the early stages of experimen-
tation with diagnostic instruments which penetrate the uterine cavity one may ordi-
narily assume that in some cases labor will be induced prematurely. Thus, in the
early stages of development of such techniques as amniocentesis and fetoscopy, re-
searchers have preferred to do this shortly before initiation of a procedure to
terminate pregnancy. In the view of researchers, the greatest harm that might
befall such a fetus is that its abortion might be induced an hour or perhaps a day
earlier than it would otherwise. For a discussion of the consequences of not pro-
ceeding with this sort of research, see Mahoney, Implications of Restrictions on Fetal
Research for Biomedical Advance, 23 CLINICAL RESEARCH 229-32 (1975).
15. For the first draft of the proposal, see 38 Fed. Reg. 31,738-49 (1973). This
draft was revised and republished as a proposal. 39 Fed. Reg. 30,653-57 (1974).
16. The Department of Health, Education, and Welfare received 450 responses
to its November 16, 1973 proposal of regulations. See 39 Fed. Reg. 30,648 (1974).
For a detailed account of the problems perceived by the biomedical research community
with these proposed regulations, see the position statements of the American Federa-
tion for Clinical Research, reprinted in 22 CLINICAL RESEARCH 135-38 (1974) and
"23 CLINICAL RESEARCH 53-60 (1975).
17. See Levine, Proposed Rules on Ethics of Human Experimentation: Tensions
Between the Biomedical Research Community and the United States Federal Govern-.
ment, in SOCIAL RESEARCH IN CONFLICT WITH LAW AND ETHICS 67-81 (P. Nejelski
ed. 1976).
5
Levine: The Impact on Fetal Research of the Report of the National Commis
Published by Villanova University Charles Widger School of Law Digital Repository, 1977
VILLANOVA LAW REVIEW
a formidable bureaucracy which probably would not have contributed
materially to the avowed purpose of safeguarding the rights and wel-
fare of human subjects. Further, in some cases they might have
achieved results contrary to this purpose. Among the new bureau-
cratic structures that would have been created was the Ethical Ad-
visory Board (EAB) which - because it would have reviewed all
research on persons with limited capacities to consent - would have
largely duplicated the efforts of the Institutional Review Board (IRB).
There was also a proposal to establish Consent Committees to monitor
the negotiations for informed consent between investigators and prospec-
tive subjects and, further, to monitor the ongoing research activity.'
In the view of some investigators, this proposal would have resulted
in the overregulation of research, the trivialization of medical ethics,
and the paper documentation of apparent - as opposed to actual -
protection of the rights and welfare of human subjects.'9 Rather than
waste so much time and energy, many investigators diverted their
energies to less tedious pursuits.
Second, the proposed regulations would have created various new
bureaucratic structures and assigned new functions to existing ones.
These changes seemed to reflect a prevailing climate of mistrust.20 It
did not seem to the biomedical research community that this assumption
of mistrust had any legitimate support in actual experience.
Finally, some specific proposals to foreclose categories of research
seemed particularly dangerous. For example, there was to be a uniform
proscription of all research initiated prior to the procedure to terminate
pregnancy. 21 Even though these proposals were not final regulations
many investigators behaved as if they were. Thus, shortly after publi-
cation of these proposals there was a sharp reduction in the amount of
important research done in this category.
In July 1974, Congress passed the National Research Act which
contained the "moratorium" on fetal research: "Until the Commission
has made its recommendations ...the Secretary may not conduct or
support research . ..on a living human fetus, before or after the
18. See 39 Fed. Reg. 30,654 (1974).
19. See generally Ingelfinger, The Unethical in Medical Ethics, 83 ANNALS
INTERNAL MED. 264-69 (1975). For a detailed analysis of the problems presented by
one NIH policy, see Holder & Levine, Informed Consent for Research on Specimens
Obtained at Autopsy or Surgery: A Case Study in the Overprotection of Human
Subjects, 24 CLINICAL RESEARCH 68-77 (1976).
20. This sense of not being trusted by either the public or the government is
reflected in the statements of hospital administrators and doctors as reported in the
New York Times immediately following the arrest of four doctors for "grave robbing."
See N.Y. Times, Apr. 19, 1974, at 42, col. 4; id. Apr. 20, 1974, at 1, col. 1; id. Apr.
21, 1974, § IV, at 11, col. 1; text accompanying notes 23 & 24 infra.
21. See 39 Fed. Reg. 30,654 (1974).
[VOL. 22 : p. 297
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induced abortion of such fetus, unless such research is done for the
purpose of assuring the survival of such fetus."'22 Elsewhere in the
legislation, the Commission was instructed to deliver its recommenda-
tions on fetal research within four months of its having been convened.
Because of delays in convening the Commission and the time needed for
the Commission to formulate its recommendations, the actual mora-
torium which the Commission recommended lifting, continued for
approximately ten months.
It is difficult for those who are not involved in either the conduct
or the administration of research to imagine the impact of a moratorium.
It takes a long time to assemble a team of people having the expertise
necessary to do sophisticated research. It also takes a long time to
acquire ample space and adequate instruments to conduct this research.
The personnel, space, and instruments may all be viewed as very
valuable and quite scarce resources; if they are not employed for one
purpose, they will generally be employed for another. During the ten
month moratorium the personnel, space, and instruments that had
previously been committed to doing fetal research were, in some cases,
committed either to doing other sorts of research or to nonresearch
purposes. At the end of the moratorium it became necessary for in-
vestigators to again begin seeking funding for research - e.g., to pay
the salaries of highly skilled technicians and other personnel - and to
secure laboratory space commitments from institutional administrators
who had assigned the space to other projects for which funding seemed
more stable and secure. This moratorium had a particularly chilling
effect. It was imposed at a time when the NIH was in the final stages
of planning the programs which would have provided contracts for
the development of such techniques as fetoscopy. The research com-
munity anticipated that these large contract programs would have
provided a relatively stable source of support for ongoing activities.
Several substantial research operations were dismantled, and those
administrators and investigators who had been involved in them have
been quite loathe to begin again.
In 1973, an article published in the New England Journal of
Medicine reported on a research project which involved the administra-
tion of antibiotics to pregnant women shortly before initiation of
therapeutic abortions and the subsequent examination of aborted
fetuses.23 The objective was to determine which of two antibiotics
22. Pub. L. No. 93-348, Title II, § 213, 88 Stat. 353 (1974).
23. Philipson, Sabath & Charles, Transplacental Passage of Erythromycin and
Clindamycin, 228 NEw ENG. J. MED. 1219-21 (1973). This particular project is an
example of the first type of research discussed in note 14 supra in which the proposed
1976-1977]
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concentrated most effectively in the fetus, with an aim toward pre-
dicting which might prove most useful in the treatment of such in-
fectious diseases as syphilis. Since reports of similar studies of different
drugs had been published previously in reputable medical journals,
one would not have anticipated the ensuing legal consequences. Dr.
Sabath and the other authors were indicted for "grave robbing,"24 and
they are still awaiting trial. Shortly thereafter, legislation was enacted
in Massachusetts making this important category of research a felony ;'-
several other states have since adopted similar laws. 26
While searching for the fetuses described by Sabath, repre-
sentatives of the Boston prosecutor's office found a fetus that had been
aborted by Dr. Kenneth Edelin" Dr. Edelin was convicted of man-
slaughter on February 15, 1975.28 This conviction was rendered in
the face of conflicting evidence by eyewitnesses as to whether the fetus
in question showed any of the "signs of life."'2 9 Most fetuses exhibiting
less than all of the signs of life - i.e., spontaneous muscle movement,
respiration, heartbeats and pulsating umbilical cords - are nonviable;
that is to say that they have no chance whatsoever of survival." Yet,
as a consequence of this highly publicized conviction, there is now a
strong tendency to perform abortions using techniques that will guaran-
tee that there will be no signs of life. These techniques, in general,
render the aborted fetus useless for the kinds of research activities
that require the availability of larger fetuses which are living and yet
nonviable.8 The legal forces which diminished the availability of
such fetuses beginning with the decisions in Roe and Doe, were greatly
accelerated by the Edelin decision. 2
objective cannot be achieved unless the fetus can be examined shortly after it is
aborted. The tendency of the Roe and Doe decisions to facilitate this type of research
was substantially offset by the indictment of these authors.
24. N.Y. Times, Apr. 14, 1974, § IV, at 7, col. 1.
25. See MASS. GEN. LAWS ANN. ch. 112, § 12J (West) (Supp. 1976-77)
(amended).
26. For a survey of state laws relating to fetal research, see Capron, The Law
Relating to Experimentation with the Fetus, in NATIONAL COMMISSION FOR THE
PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND BEHAVIORAL RESEARCH,
Appendix to REPORT AND RECOMMENDATIONS: RESEARCH ON THE FETUS (DHEW
Pub. No. (OS) 76-128, 1975).
27. See Culliton, Manslaughter: The Charge Against Edelin of Boston City
Hospital, 186 SCIENCE 327-30 (1974).
28. For a detailed account of the Edelin trial, see Culliton, Edelin Trial: Jury
Not Persuaded by Scientists for the Defense, 187 SCIENCE 814-16 (1975).
29. Id.
30. For a discussion of the signs of life and their relative importance in deter-
mining the viability of a fetus ex utero, see Levine, supra note 5.
31. See text accompanying note 8 supra.
32. On December 17, 1976, the Massachusetts Supreme Judicial Court set aside
the conviction of Dr. Edelin. Commonwealth v. Edelin, __ Mass. -, 359 N.E.2d 4
374 [VOL. 22 : p. 297
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Thus, several events which antedated the Commission's Report
tended to discourage fetal research. In the absence of some dramatic
encouragement, it appears unlikely that there will be any substantial
recovery in the level of activity of fetal research in the near future.
Directors of some of the leading programs in obstetrics and gynecology
have reported a sharp reduction in research interest on the part of
physicians seeking training in their field.8" Young physicians who are
interested in doing research are being attracted to other medical special-
ties.
C. Impact of the Commission's Report
In order to analyze the impact of the Commission's Report, its
recommendations will be compared with previous expressions of public
policy made at a national level: the National Research Act 4 and the
proposed HEW regulations on fetal research. 5 A detailed comparison
of the Commission's recommendations with the second draft of the
HEW proposed regulations reveal that in each case in which the
former is at variance with the latter, the effect of the Commission's
recommendations was to decrease the development of pointlessly cum-
bersome procedures and needlessly restrictive proscriptions. Rather
than review all of these differences, this article will focus upon the
issues identified as the items "of gravest concern to the biomedical
research community. 6
The HEW proposal called for the development of an Ethical
Advisory Board to review "all applications or proposals for support
of . . . biomedical research, development, and related activities in-
volving: 1) the fetus in utero, 2) the abortus . . . 3) pregnant women,
and 4) in vitro fertilization. In addition, these regulations are appli-
cable to all such activities involving women who could become preg-
nant . . ."" In short, the HEW proposed regulations called for a
tremendous amount of duplication of the IRB's effort at a national level.
By contrast, the Commission recommended approval by "a national
(1976). However, it seems unlikely that the trend of avoiding the abortion of fetuses
that might show a sign of life will be reversed.
33. Conversation with Dr. Donald T. Chalkley, supra note 2.
34. Pub. L. No. 93-348, Title II, § 213, 88 Stat. 353 (1974). For a discussion
of the impact of the moratorium on fetal research, see text accompanying note 23 supra.
The Commission recommended that the moratorium on fetal research be lifted. Com-
MISSION's REPORT, supra note 1, at 300-24. However, the effects of the 10 month mora-
torium are not likely to be quickly overcome.
35. 39 Fed. Reg.'30,653-57 (1974).
36. See text accompanying notes 16-21 supra.
37. 39 Fed. Reg. 30,653 (1974) (proposed section 46.304).
1976--1977]
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ethical review body" only for nontherapeutic research directed toward
the fetus in anticipation of abortion and during the abortion procedure,
and that directed toward the nonviable fetus ex utero.38
Secondly, the Commission's recommendations did not support the
HEW proposal"0 to establish Consent Committees for fetal research.
Consequently, there is no mention of these committees in the final
HEW regulations. In addition, the HEW proposal of an absolute
proscription of nontherapeutic research in anticipation of abortion re-
gardless of whether any risk is presented to the fetus4° was not sup-
ported by the Commission. The Commission's recommendation number
five instead provided that such research may be conducted or supported
if it is done in accord with specified procedural safeguards.4'
In conclusion, the Report of the Commission should be a source
of encouragement to those who are interested in fetal research. When
considered in its historical context it may be interpreted as an effort to.
restore a rational perspective. The Commission's recommendations
contain no prohibition of any type of research that might be proposed
by a responsible investigator. To resolve the most difficult problems,.
the Commission depends heavily upon the development of a procedural'
mechanism; a national ethical review body. However, in contrast to
the HEW proposals, the recommendations do not overtax this proce-
dural mechanism with the performance of meaningless tasks. Further,
the Report does not attempt to anticipate all future research contin-
gencies and to resolve them through the development of regulations.
Rather, it provides a framework of guidelines within which the EAB
and the IRB can be expected to function. However, owing to some
of the circumstances beyond the control of the Commission, it may be
a long time, if ever, before the full positive impact of its report is
expressed.
38. COMMISSION'S REPORT, supra note 1, at 300-24. The Commission forwarded
its recommendations to the Secretary of DHEW, in May, 1975 and the final regula-
tions were published in the Federal Register on August 8, 1975. See 40 Fed. Reg.
33,526-30 (1975). The DHEW regulations called for the establishment of two,
Ethical Advisory Boards to review proposals to do fetal research in the three cate-
gories specified in the text. As of December, 1976 - 15 months later - no Ethical
Advisory Boards have been established. Perhaps one of the factors contributing to,
the absence of proposals to do research in these categories is the fact that investigators
who might wish to develop such proposals know that there is no mechanism in opera-
tion to review them.
39. 39 Fed. Reg. 30,653 (1974) (proposed section 46.305).
40. Id. (proposed section 46.306). As noted earlier, this is an extremely im-
portant class of research. See note 14 supra.
41. COMMISSION'S REoRT, supra note 1, at 312.
376 [VOL. 22 : p. 297
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II. A CONCEPTUAL FLAW: THE SPURIOUS DISTINCTION BETWEEN
THERAPEUTIC AND NONTHERAPEUTIC EXPERIMENTATION
Perhaps the greatest contribution the Commission could make to
those who wish to participate intelligently in the formulation and imple-
mentation of public policy as it relates to research involving human
subjects would be a clarification of the language used to discuss such
research. If it were to do this, the Commission's favorable impact on
the conduct of research would be greatly enhanced. Evidence that the
Commission is beginning to accomplish this salutary objective will
be discussed below.42 First, however, one serious conceptual flaw con-
tained in the Report should be identified :" The definitions upon which
the Commission's recommendations are based perpetuate the meaning-
less distinction between therapeutic and nontherapeutic research."
This is not merely a semantic problem; this spurious dichotomization
leads us to reach wrong conclusions in our ethical analyses and, as
an inevitable consequence, to develop inappropriate law.
It is not clear when this unfortunate distinction began to be made
in discussions of the ethics and regulation of research. The Nuremberg
Code makes no such distinction.45 The Declaration of Helsinki in 1964
distinguished nontherapeutic clinical research from clinical research
combined with professional care.46 In the 1975 revision of this Declara-
42. See text accompanying notes 55-64 infra.
43. In fact, there is more than one problem with the definitions contained in the
Commission's report. The Commission's report, for. example, provides no language
that can be used to discuss whether a living fetus in utero might be expected to sur-
vive after delivery. See note 6 supra.
44. COMMISSION'S REPORT, supra note 1, at 40 Fed.' Reg. 33,532 (1975). The
pertinent definitions are as follows:
"Research" refers to a systematic collection of data or observations in accord-
ance with a designed protocol.
"Therapeutic research" refers to research designed to improve the health con-
dition of the research subj ect by prophylactic, diagnostic or treatment methods that
depart from standard medical practice but hold. out a reasonable expectation
of success.
"Nontherapeutic research" refers to research not designed to improve the
health condition of the research subject.
Id. I shall not provide detailed comments on these definitions. Rather, it should
suffice to ask the reader at this point to try to imagine a ". . . systematic collection of
data or observations . . . designed to improve the health condition of a research sub-ject." Actually, since most diagnostic activity involves a systematic collection of data
or observations, it is possible to imagine some activity that would conform to the
Commission's definition. However, even this does not work well. This is because the
diagnostic activity one would have to imagine, ordinarily would not present a departure
from standard medical practice. Moreover, it clearly was not the intent of the Com-
mission to develop through these definitions the possibility of discussing ordinary
diagnostic activities.
45. Nuremberg Code of Ethics, reprinted in, Appendix, supra note 26, at 17-1
to 17-2.
46. Declaration of Helsinki (1964) (amended 1975), reprinted in Appendix, supra
note 26, at 18-1 to 18-3.
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tion, "medical research combined with professional care" is desig-
nated "clinical research" while "nontherapeutic biomedical research
involving human subjects" is designated "non-clinical biomedical re-
search."'47 Principles set forth to govern "clinical research" provide
that, "[t]he doctor can combine medical research with professional
care, the objective being the acquisition of new medical knowledge,
only to the extent that medical research is justified by its potential
diagnostic or therapeutic value for the patient."4" This is to be con-
trasted with principles developed with respect to nonclinical research:
"[t]he subjects should be volunteers - either healthy persons or
patients for whom the experimental design is not related to the patient's
illness."4 It is beyond the scope of this article even to list all of the
problems that derive from the use of this unfortunate distinction. For
present purposes, discussion will be confined to the identification of only
three such problems. These three are sufficiently serious that an aware-
ness of them should force us to conclude that we must abandon this
classification.
First, many types of research done by physicians on human sub-
jects cannot be categorized either therapeutic or nontherapeutic. Con-
sider, for example, the placebo-controlled, "double-blind" drug trial.
Certainly the administration of a placebo for research purposes is not
"justified by its potential diagnostic or therapeutic value for the
patient."'  Therefore, it is nontherapeutic. Thus, according to the
Declaration of Helsinki, those who receive the placebo must be "either
healthy persons or patients for whom the experimental design is not
related to the patient's- illness."'" This would be absurd.
Secondly, a strict' interpretation of the Declaration of Helsinki
would lead one to conclude that all rational research designed to explore
the pathogenesis of a disease is to be forbidden. If such research
cannot be justified by 'its potential diagnostic or therapeutic value for
the patient, it must be. considered nontherapeutic. Therefore, such re-
search may be performed ,only upon healthy persons or patients not
having the disease one wishes to investigate. Again, this would be
absurd.
47. Helsinki Declaration (1975) (copies can be obtained from the World Medical
Association, 1841 Broadway, New York, New York 10023).
48. Id. (Principle 1.6j. In recent years, we have seen the distinction between
therapeutic and nontherapeutic research assume a central position in the papers of
those who discuss the ethics or law of research involving human subjects. See, e.g.,
C. FRIED, MEDICAL EXPERIMENTATION (1974); P. RAMSEY, THE PATIENT AS A
PERsoN (1970).
49. Id. (Principle 111.2).
50. Helsinki Declaration (.i975) (copies can be obtained from the World Medical
Association, 1841 Broadway, New York, New York 10023).51. Id.
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Paul Ramsey provides us with a good example of how one can
be lead to erroneous conclusions by assuming that there is a distinction
between therapeutic and nontherapeutic research. He claims that the
use of a nonconsenting subject is wrong whether or not there is risk,
simply because it involves an "unconsented touching. '52 This wrong-
ful touching is rectified only when it is done for the good of the indi-
vidual. Thus, based upon the assumption that therapeutic research
is always done for the good of the individual subject, he concludes that
proxy consent is permissible for therapeutic research. 53  He further
concludes that nontherapeutic research on children is never justified
because they cannot consent for themselves and the potential benefit
to the subject that would validate proxy consent to therapeutic research
is lacking.54
In order to avoid these embarrassments we must abandon the
distinction between therapeutic and nontherapeutic research. The Com-
mission has begun to do this. In its later report, Research Involving
Prisoners,55 the terms therapeutic and nontherapeutic research are not
used. The language used in this later report should provide much more
suitable guidance to those who develop regulations, to IRB members,
and to investigators. But before the Commission was able to clarify
its use of terminology, it Was necessary for it to begin to systematically
address the general conceptual charges in its mandate.56 If the Com-
mission had had the opportunity to begin its general conceptual con-
siderations before addressing the specific problems of research on the
fetus, the terms therapeutic and nontherapeutic research might not
have been perpetuated.
Subsequent to the publication of Research on the Fetus, the Com-
mission drafted its definitions of research,57 practice,5 and a third class
52. P. RAMSEY, supra note 48, at 11.
53. Id. at 11-12.
54. Id. at 13.
55. NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF Bio-
MEDICAL AND BEHAVIORAL RESEARCH, REPORT AND RECOMMENDATIONS: RESEARCH
INVOLVING PRISONERS (DHEW Pub. No. (OS) 76-131, 1975).
56. In the National Research Act, the Commission is charged to "consider,"
among other things: "The boundaries between biomedical or behavioral research
involving human subjects and the accepted and routine practice of medicine." Pub.
L. No. 93-348, Title II, § 202(a) (1) (B) (i), 88 Stat. 349 (1974).
57. The term "research" is defined as follows:
Biomedical and behavioral research involving human subjects refers to a class of
activities designed to develop or contribute to generalizeable knowledge. By
generalizeable knowledge we mean theories, principles or relationships (or the
accumulation of data on which they may be based). that can be corroborated by
accepted scientific observation and inferences.
National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research, The Boundaries Between Biomedical or Behavioral Research
and Accepted and Routine Practice (draft document, Feb. 24, 1976) (on file at the
1976-1977]
13
Levine: The Impact on Fetal Research of the Report of the National Commis
Published by Villanova University Charles Widger School of Law Digital Repository, 1977
VILLANOVA LAW REVIEW
of activities, innovative therapy, which definition is especially relevant
here:
[0] ther uncertainties may be introduced by the application of novel
procedures as, for example, when deviations from common prac-
tice in drug administration or in surgical, medical or behavioral
therapies are tried in the course of rendering treatment. These
activities may be designated innovative therapy, but they do not
constitute research unless formally structured as a research proj-
ect . . . . [T]here is concern that innovative therapies are being
applied in an unsupervised way, as part of practice. It is our recom-
mendation that significant innovations in therapy should be in-
corporated into a research project in order to establish their safety
and efficacy while retaining the therapeutic objectives."
It is made clear in other parts of this draft statement that diagnostic
and prophylactic maneuvers are included under this rubric. 0 Thus, a
more descriptive title for this' class of activities might be "innovative
practices."
In subsequent discussion by the Commission, it has been made
apparent that novelty is not the attribute that defines this class of
practices; rather, it is-the lack of suitable validation of the safety or
efficacy of the practice.6 ' Therefore, it is proposed that the best desig-
nation for this class of activities, is "nonvalidated practice." A practice
might be nonvalidated because it is new; i.e., it has not been tested
sufficiently often or sufficiently well to permit a satisfactory prediction
of its safety or efficacy in a patient population. An equally common
way for a practice to merit the designation nonvalidated is when, in
the course of its use in the practice of medicine, some legitimate ques-
tion arises concerning previously held assumptions about its safety
offices of the National Commission for the Protection of Human Subjects of Bio-
medical and Behavioral Research, Westwood Building, Room 125, 5333 Westbard
Avenue, Bethesda, Maryland 20016).
58. The term "practice" is defined as follows:
[T]he practice of medicine or behavioral therapy refers to a class of activities
designed solely to enhance the well-being of an individual. The customary stand-
ard for routine and accepted practice is a reasonable expectation of success.
The absence of validation or precision on which to base such an expectation,
however, does not in 'and of itself define the activity in question as research.
Uncertainty is inherent in therapeutic practice because of the variability of





61. See transcripts of, the recent meetings of the National Commission for the
Protection of Human Subjects of Biomedical and Behavioral Research (on file at the
offices of the National Commission for the Protection of Human Subjects of Bio-
medical and Behavioral Research, Westwood Building, Room 125, 5333 Westbard
Avenue, Bethesda, Maryland 20016).
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and/or efficacy. The source of the problem might be that the practice
was never validated adequately in the first place, that a question is
raised of previously unknown serious toxicity, or that a new practice
seems likely to be either more safe or more effective. At the time of
the first substantial challenge to the validity of a previously accepted
practice, continuing use of that practice should be considered non-
validated. For purposes of developing ethical norms, guidelines, or
regulations, all nonvalidated practices may be considered together. As
the Commission has suggested in the case of innovative therapy, these
practices should be conducted in the context of a research project
designed to test their safety and efficacy; however, the research should
not interfere with the basic therapeutic (or diagnostic or prophylactic)
objectives. 2
When research is done to test the safety or efficacy of a non-
validated practice, the relationship between the physician-investigator
and patient-subject is more complex than in either a physician-patient
or investigator-subject relationship. In order to determine whether it is
justified to proceed with the total activity or with any of its component
parts, it is necessary to analyze each of the component parts for what
it really is. The employment of a nonvalidated practice is not in and of
itself research, although it may be malpractice. 63
Nonvalidated practice has much more in common with validated
practice than it has with research. The decision to use a nonvalidated
diagnostic procedure or therapeutic modality should ordinarily be
made in the same way one makes the decision to use a validated pro-
cedure. That is, of the various modalities or procedures available to
accomplish the purpose agreed upon by the physician and patient, the
physician chooses the one which seems most likely to achieve the
shared objective and least likely to produce adverse effects. When
deciding to use nonvalidated procedure, it makes sense to talk about
alternatives, as is required by the HEW regulations on informed
consent.6" A choice between the various alternatives may be based
62. Research designed to test the safety and/or efficacy of nonvalidated practices
includes those activities ordinarily referred to as therapeutic research. It also includes
such nontherapeutic maneuvers as placebo administration, randomization, and so on.
63. I wish to reemphasize that nonvalidated practices should ordinarily be con-
ducted in the context of a research project designed to test their safety and efficacy.
The conduct of such activities should adhere to the standards established for research -
most importantly, an Institutional Review Board should review proposals to proceed.
The Institutional Review Board should determine whether there are compelling
reasons to depart from other standards of research; e.g., adherence to such standards
would be to the detriment of the therapeutic objective. The employment of a non-
validated practice without approval by an Institutional Review Board might appro-
priately - if not technically - be considered malpractice.
64. 45 C.F.R. 46.3(c) (4) (1975).
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upon those factors that seem most important -to the patient; e.g., risk,
benefit, inconvenience, and expense. In research, on the other hand,
there are no alternatives between which one might choose. The only
alternatives are to proceed with the research or not to proceed. In the
complex activity which is commonly called therapeutic research, the
components that would properly be called research are those designed
to establish the safety and/or efficacy of the nonvalidated practice.
These are virtually never done for the benefit of the individual patient
or subject. They are always designed to contribute to generalizeable
knowledge. While research activities can always be rejected without
jeopardy to the life or health of the patient, the nonvalidated practice
often cannot. The requirement for an explication of alternatives -
derived from the medical practice model - clearly is inapplicable to
research.
III. SUMMARY AND CONCLUSIONS
In the past three years there has been a substantial decrease in
the amount of fetal research performed in the United States. This de-
crease reflects the effects of multiple social and political forces that
were operative before the Commission was convened and which con-
tinued during its deliberations. By the time the Commission was
convened, the situation seemed quite dark to those who wished to
conduct fetal research; it is most unlikely that the Commission could
have made any recommendations that might have been more dis-
couraging to them.
A detailed comparison of the Commission's Report with previous
expressions of public policy made at a national level, however, indi-
cates that, in general, the Commission recommended a decrease in the
development of pointlessly cumbersome procedures and needlessly
restrictive proscriptions. Thus, when considered in its historical con-
text, the Report of the Commission may be viewed as an effort to
restore a rational perspective to the development of public policy on
fetal research.
Perhaps the greatest contribution the Commission could make to
those who wish to participate intelligently in the formulation and
implementation of public policy as it relates to research involving
human subjects would be a clarification of the language used to dis-
cuss it. Some semantic and conceptual flaws that have become firmly
entrenched in the language used to discuss research and its regulation
are unfortunately incorporated in the Commission's Report on Research
on the Fetus. Since the Commission issued that report, however, it
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has begun to consider systematically the general conceptual charges
in its mandate. This has begun to yield a clarification of the language
we use to discuss research.6 5 Consequently, the language used in the
Commission's Report on Research Involving Prisoners should provide
much more suitable guidance to those who develop regulations, to
members of Institutional Review Boards, and to investigators.
65. See NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF
BIOMEDICAL AND BEHAVIORAL RESEARCH, REPORT AND RECOMMENDATIONS: RESEARCH
INVOLVING PRISONERS (DHEW Pub. No. (OS) 76-131, 1976).
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